Keyphrases
Bronchiectasis
100%
Interim Analysis
35%
Neisseria Species
35%
Nontuberculous Mycobacterial Lung Disease
35%
Pathobiont
35%
Interstitial Lung Disease
35%
Respiratory Disease
35%
Macrolide Antibiotics
35%
Multi-cohort Studies
35%
Lung Abnormalities
35%
COVID-19 Hospitalization
35%
Proteomics
35%
Blood Eosinophil Count
35%
Sputum
35%
Immunomodulatory Effect
35%
Post-COVID-19
35%
Cystic Fibrosis
32%
Credible Interval
29%
Mycobacterium Tuberculosis (M. tb)
27%
Rehospitalization
23%
COVID-19
23%
Risk Ratio
17%
Macrolides
17%
Mechanism of Action
17%
Inflammatory Lung Disease
17%
Pseudomonas Aeruginosa (P. aeruginosa)
16%
Eosinophil Count
15%
Asthma
14%
Neisseria
13%
Nontuberculous Mycobacterial Infection
11%
Computed Tomography
11%
Sensitivity Analysis
11%
Risk Factors
11%
Protein Profile
11%
Risk Strata
11%
Confidence Interval
10%
Hazard Ratio
10%
Pseudomonas
9%
Inconsistent Data
8%
Clinically Significant
8%
Incomplete Understanding
8%
Immunomodulatory Mechanisms
8%
Lung Disease
8%
COVID-19 Infection
8%
Immunomodulatory Therapy
8%
Neisseria Subflava
8%
Immunomodulatory
8%
Immunomodulatory Properties
8%
Antibacterial Effect
8%
Antibacterial Properties
8%
Treatment Response
7%
COVID-19 Related
5%
Lung Fibrosis
5%
Ventilation Support
5%
Genetic Architecture
5%
Functional Consequences
5%
Thoracic Computed Tomography
5%
Health Care Services
5%
Hospitalization
5%
Binomial Distribution
5%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
5%
Ultra-high Risk
5%
Ground-glass Opacity
5%
At-risk Individuals
5%
Binomial Regression
5%
Lung Damage
5%
Chest X-ray
5%
Phase II Trial
5%
Clinical Trials
5%
Infection Rate
5%
Non-cystic Fibrosis Bronchiectasis
5%
Neutrophilic Disorders
5%
Elevated Eosinophils
5%
Increased Mortality
5%
Sputum Eosinophil Count
5%
Pseudomonas Aeruginosa Infection
5%
Clinical Entities
5%
Eosinophils
5%
Clinical Phenotype
5%
Multiple Datasets
5%
Patient-Reported Outcomes Measurement Information System (PROMIS)
5%
Bronchiectasis Exacerbation
5%
Sputum Microbiome
5%
16S rRNA Sequencing
5%
Confounding Effect
5%
Antipseudomonal Antibiotics
5%
Microbial Profile
5%
Medicine and Dentistry
Silo-Filler's Disease
35%
Sputum
35%
Interim Analysis
35%
Post-COVID-19
35%
Interstitial Lung Disease
35%
COVID-19
35%
Lung
35%
Proteomics
35%
Cystic Fibrosis
21%
Chronic Obstructive Pulmonary Disease
21%
Bronchiectasis
17%
Prevalence
17%
Computer Assisted Tomography
17%
Infection
13%
Biological Marker
10%
Diseases
9%
Treatment Response
7%
Pseudomonas aeruginosa
7%
Mycobacterial Infection
7%
Ground Glass Opacity
5%
Chest Radiograph
5%
Coronavirinae
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Pulmonary Fibrosis
5%
Health Service
5%
Immunology and Microbiology
Sputum
42%
Neisseria
35%
Eosinophil Count
35%
Proteomics
35%
Microbiome
11%
Pseudomonas aeruginosa
10%
Infectious Agent
8%
Pseudomonas
8%